ISKJ.ME

Institut Stvolovykh Kletok Cheloveka PAO [ISKJ.ME] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ISKJ.ME Stock Summary

ISKJ.ME's dividend payments are well covered by cash flows with cash payout ratio of 0.21%.

Has a high level of debt. Debt-to-Equity ratio of 2.13 is considered high.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

ISKJ.ME has less than 1 year of cash runway

In the News

ISKJ.ME Financial details

Company Rating

Neutral

Market Cap

4.86B

Income

78.25B

Revenue

2368.41B

Book val./share

Cash/share

Dividend

Dividend %

3.36%

Employees

Optionable

Shortable

Yes

Earnings

31 Dec 2021

P/E

224.26

Forward P/E

PEG

14.49

P/S

4.27

P/B

15.17

P/C

P/FCF

57.59

Quick Ratio

0.71

Current Ratio

1.74

Debt / Equity

2.13

LT Debt / Equity

0.87

EPS (TTM)

1.07

EPS next Y

EPS next Q

EPS this Y

-35.71%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

12.01%

Revenue Q/Q

12.08%

EPS Q/Q

-60.53%

SMA20

23.19%

SMA50

30.77%

SMA100

Inst Own

Inst Trans

ROA

ROE

ROC

0.07%

Gross Margin

77%

Oper. Margin

10%

Profit Margin

Payout

Shs Outstand

81.61M

Shs Float

28.41M

Target Price

52W Range

59.12-77.1

52W High

-22.68%

52W Low

+0.92%

RSI

Rel Volume

Avg Volume

Volume

261.91K

Perf Week

-35.39%

Perf Month

-9.65%

Perf Quarter

Perf Half Y

Beta

1.011

Volatility

10.24%, 11.47%

Prev Close

-29.3%

Price

59.54

Change

-29.52%

ISKJ.ME Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	8.6	11.14	14.45	14.76	13.08
Net income per share	-0.46	1.13	1.38	0.42	0.27
Operating cash flow per share	0.26	2.34	0.72	3.51	2.53
Free cash flow per share	-0.21	-0.27	-0.42	1.59	0.97
Cash per share	2.73	2.54	1.7	2.73	3.25
Book value per share	0.36	1.32	2.59	2.93	3.92
Tangible book value per share	-2.6	-0.66	-0.59	-1.03	-1.92
Share holders equity per share	0.36	1.32	2.59	2.93	3.92
Interest debt per share	5.4	6.21	7.05	8.35	10.35
Market cap	597M	974.25M	2.86B	9.19B	6.7B
Enterprise value	907.05M	1.31B	3.24B	9.62B	7.33B
P/E ratio	-17.45	11.52	27.68	274	290.4
Price to sales ratio	0.93	1.17	2.64	7.78	5.89
POCF ratio	30.74	5.55	53.13	32.73	30.42
PFCF ratio	-37.51	-47.45	-90.18	72.09	79.42
P/B Ratio	22.09	9.87	14.73	39.15	19.65
PTB ratio	22.09	9.87	14.73	39.15	19.65
EV to sales	1.41	1.57	2.99	8.14	6.45
Enterprise value over EBITDA	7.09	6.26	14.61	55.35	38.46
EV to operating cash flow	46.7	7.45	60.21	34.24	33.28
EV to free cash flow	-56.99	-63.74	-102.19	75.42	86.89
Earnings yield	-0.06	0.09	0.04	0	0
Free cash flow yield	-0.03	-0.02	-0.01	0.01	0.01
Debt to equity	13.86	4.3	2.51	2.63	2.44
Debt to assets	0.33	0.3	0.32	0.36	0.41
Net debt to EBITDA	2.42	1.6	1.72	2.44	3.3
Current ratio	1.15	1.05	1.04	1.77	1.74
Interest coverage	3.88	4.34	3.66	1.82	1.64
Income quality	-1.06	1.58	0.52	8.37	9.55
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.04	0.05	0.02	0.03	0.03
Research and developement to revenue	0.05	0.03	0	0.01	0.07
Intangibles to total assets	0.28	0.3	0.3	0.31	0.36
Capex to operating cash flow	-1.82	-1.12	-1.59	-0.55	-0.62
Capex to revenue	-0.05	-0.23	-0.08	-0.13	-0.12
Capex to depreciation	-1.19	-3.27	-1.14	-1.89	-2.54
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.92	5.78	8.96	5.26	4.84
ROIC	0.1	0.3	0.2	0.11	0.07
Return on tangible assets	-0.04	0.09	0.1	0.03	0.02
Graham Net	-9.72	-10.02	-11.38	-11.69	-12.42
Working capital	61.04M	22.19M	19.81M	285.9M	294.2M
Tangible asset value	-194.68M	-49.13M	-44.05M	-82.12M	-166.47M
Net current asset value	-528.79M	-518.67M	-521.16M	-618.63M	-784.54M
Invested capital	13.86	4.3	2.51	2.63	2.44
Average receivables	0	0	0	0	0
Average payables	97.14M	102.08M	90M	99.84M	84.58M
Average inventory	130.86M	155.27M	203.1M	239.66M	234.83M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	557.57	183.58	114.55	128.87	93.94
Days of inventory on hand	632.62	383.57	274.8	309.57	314.65
Receivables turnover	0	0	0	0	0
Payables turnover	0.65	1.99	3.19	2.83	3.89
Inventory turnover	0.58	0.95	1.33	1.18	1.16
ROE	-1.27	0.86	0.53	0.14	0.07
Capex per share	-0.47	-2.62	-1.14	-1.92	-1.56

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2021-06-30	2021-12-31	2022-06-30	2022-12-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.64	8.5	0	0	0
Net income per share	0.38	0.15	0	0	0
Operating cash flow per share	0.51	2.71	0	0	0
Free cash flow per share	-0.23	0.76	0	0	0
Cash per share	0	0	0	0	0
Book value per share	0	0	0	0	0
Tangible book value per share	0	0	0	0	0
Share holders equity per share	0	0	0	0	0
Interest debt per share	0.39	0.49	0	0	0
Market cap	2790.04B	8432.48B	0	0	0
Enterprise value	2790.46B	8432.9B	563.58M	629.94M	449.97M
P/E ratio	24.92	195.78	0	0	0
Price to sales ratio	5.01	13.51	0	0	0
POCF ratio	75.12	42.36	0	0	0
PFCF ratio	-169.93	150.62	0	0	0
P/B Ratio	12.5K	35.92K	0	0	0
PTB ratio	12.5K	35.92K	0	0	0
EV to sales	5.01	13.51	0	0	0
Enterprise value over EBITDA	34.76	116.79	0	0	0
EV to operating cash flow	75.13	42.36	0	0	0
EV to free cash flow	-169.95	150.63	0	0	0
Earnings yield	0.01	0	0	0	0
Free cash flow yield	-0.01	0.01	0	0	0
Debt to equity	2.14	2.63	2.25	2.44	2.13
Debt to assets	0.32	0.36	0.36	0.41	0.34
Net debt to EBITDA	0.01	0.01	0	0	0
Current ratio	1.32	1.77	1.98	1.74	2.09
Interest coverage	1.55	0.78	0	0	0
Income quality	1.88	-24.63	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.33	0.31	0.33	0.36	0.32
Capex to operating cash flow	-1.44	-0.72	0	0	0
Capex to revenue	-0.1	-0.23	0	0	0
Capex to depreciation	-1.46	-3.22	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.16	0.1	0	0	0
ROIC	61.89	27.94	0	0	0
Return on tangible assets	27.76	9.01	0	0	0
Graham Net	-0.01	-0.01	0	0	0
Working capital	127.99M	285.9M	288.71M	294.2M	496.55M
Tangible asset value	-40.59M	-82.12M	-90.8M	-166.47M	69.1M
Net current asset value	-518.02M	-618.63M	-680.6M	-784.54M	-591.3M
Invested capital	2.14	2.63	2.25	2.44	2.13
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0.02	0.01	0	0	0
Days payables outstanding	0.02	0.02	0	0	0
Days of inventory on hand	0.06	0.05	0	0	0
Receivables turnover	5.68K	7.52K	0	0	0
Payables turnover	4.5K	4.29K	0	0	0
Inventory turnover	1.59K	1.79K	0	0	0
ROE	125.41	45.86	0	0	0
Capex per share	-0.74	-1.95	0	0	0

ISKJ.ME Dividend History

ISKJ.ME Frequently Asked Questions

What is Institut Stvolovykh Kletok Cheloveka PAO stock symbol ?

Institut Stvolovykh Kletok Cheloveka PAO is a RU stock and trading under the symbol ISKJ.ME

What is Institut Stvolovykh Kletok Cheloveka PAO stock quote today ?

Institut Stvolovykh Kletok Cheloveka PAO stock price is $59.54 today.

Is Institut Stvolovykh Kletok Cheloveka PAO stock public?

Yes, Institut Stvolovykh Kletok Cheloveka PAO is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Market Capitalization 4.86B
CEO Mr. Prikhodko Alexander Viktorovich Ph.D.
Headquarters Moscow,RU
IPO Date 2010-03-03
Website https://hsci.ru

Public Joint-Stock Company Human Stem Cells Institute' operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. The company was founded in 2003 and is based in Moscow, Russia. Public Joint-Stock Company Human Stem Cells Institute' is a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.